Enanta Pharmaceuticals
ENTA· Manufacturing· Fiscal year ends in September
Jay R. Luly, Ph.D. is the CEO of Enanta Pharmaceuticals and was paid $2.8M in FY2025 (Sep), up 3%.
Executives3
See all- 1Jay R. Luly, Ph.D.President and Chief Executive OfficerFY2025
- 2Yat Sun Or, Ph.D.Chief Scientific OfficerFY2022
- 3Scott T. Rottinghaus, M.D.Chief Medical OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allEnanta Pharmaceuticals paid its 2 named executives $4.1M in total in FY2025 (Sep). CEO Jay R. Luly, Ph.D. was paid $2.8M of that.
| Name | |||
|---|---|---|---|
| Jay R. Luly, Ph.D.President and Chief Executive Officer | |||
| Scott T. Rottinghaus, M.D.Chief Medical Officer | |||
| Yat Sun Or, Ph.D.Chief Scientific Officer | Not disclosed | Not disclosed | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers21
See allThe FY2025 (Sep) proxy of Enanta Pharmaceuticals names 21 peer companies for pay. Among Enanta Pharmaceuticals and these peers, CEO pay was 8th highest of 11 and total shareholder return was 8th highest of 11.
8th highest of 11in Enanta Pharmaceuticals and its pay peers, FY2025 (Sep) by CEO pay:
8th highest of 11in Enanta Pharmaceuticals and its pay peers, FY2025 (Sep) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Activity
Filings6
See all| Proxy statement | DEF 14A | Jan 26, 2026 | FY2025 |
| Annual report | 10-K | Nov 19, 2025 | FY2025 |
| Proxy statement | DEF 14A | Jan 27, 2025 | FY2024 |
| Annual report | 10-K | Nov 27, 2024 | FY2024 |
| Proxy statement | DEF 14A | Jan 26, 2024 | FY2023 |
| Annual report | 10-K | Nov 22, 2023 | FY2023 |
